1. Clinical & Scientific Overview
Bisacodyl (TIP-MED-000077, Reference Code [5.9]) is classified under
Gastrointestinal & Hepatobiliary Medicines (Ch 05) as a Diphenylmethane Stimulant Laxative (Colonic Myenteric Plexus Stimulator).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 05 [5.9], p. 64): Dulcolax / Dulcoflex (Sanofi), Julax (Zydus), Conlax — Strengths & Dosage Forms: Enteric-Coated (Gastro-Resistant) Tablets: 5 mg; Rectal Suppositories: 5 mg (paediatric), 10 mg (adult)
Enteric-Coated (Gastro-Resistant) Tablets: 5 mg; Rectal Suppositories: 5 mg (paediatric), 10 mg (adult)
3. Mechanism of Action & Pharmacodynamics
Diphenylmethane Stimulant Laxative (Colonic Myenteric Plexus Stimulator) acting on target receptor/enzyme pathways in Gastrointestinal & Hepatobiliary Medicines (Ch 05): clinical efficacy is mediated via Diphenylmethane Stimulant Laxative (Colonic Myenteric Plexus Stimulator) for Short-term relief of acute episodic or opioid-induced constipation; bowel evacuation prior to radiological, endoscopic (colonoscopy), or surgical procedures..
4. Therapeutic Indications & Evidence-Supported Uses
- Short-term relief of acute episodic or opioid-induced constipation
- bowel evacuation prior to radiological, endoscopic (colonoscopy), or surgical procedures
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Oral: 5 mg to 10 mg (1–2 tablets) once daily at bedtime (produces bowel movement in 6 to 12 hours the next morning). Rectal Suppository: 10 mg once daily (produces bowel movement within 15 to 60 minutes). Follow physician prescription.
Administration & Meal Timing: Oral EC Tablet: Swallow whole with water at bedtime. CRITICAL MILK & ANTACID BAN: Never take within 1 hour of milk, dairy products, antacids, or PPIs/H2-blockers! | Oral: At bedtime (10:00 PM) for predictable morning evacuation (06:00–08:00 AM).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal & Hepatic: Minimal systemic absorption (<5%), but electrolyte and fluid losses from excessive purging can precipitate acute kidney injury or hypokalaemic hepatic encephalopathy.
Renal & Hepatic: Minimal systemic absorption (<5%), but electrolyte and fluid losses from excessive purging can precipitate acute kidney injury or hypokalaemic hepatic encephalopathy.
Renal & Hepatic: Minimal systemic absorption (<5%), but electrolyte and fluid losses from excessive purging can precipitate acute kidney injury or hypokalaemic hepatic encephalopathy.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in acute surgical abdomen, intestinal obstruction, ileus, appendicitis, acute inflammatory bowel disease, and severe dehydration.
Key Clinical Precautions: Renal & Hepatic: Minimal systemic absorption (<5%), but electrolyte and fluid losses from excessive purging can precipitate acute kidney injury or hypokalaemic hepatic encephalopathy.
8. Adverse Effects Profile
- Griping lower abdominal cramps/colic (especially if coating dissolves early), watery diarrhoea, rectal burning/tenesmus (with suppository).
- Electrolyte depletion (hypokalaemia, metabolic alkalosis/acidosis), dehydration, orthostatic syncope during nocturnal defecation, cathartic colon with chronic abuse.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Antacids, PPIs, H2-blockers, and Milk/Dairy raise gastric pH above 5
- 5, causing the enteric polymer coat to dissolve prematurely in the stomach—resulting in severe gastric irritation, vomiting, and upper abdominal cramping! Diuretics, corticosteroids, and digoxin (additive hypokalaemia risk with chronic overuse)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Swallow the tiny yellow Dulcoflex tablet whole with plain water only—NEVER chew or crush it, and NEVER wash it down with bedtime warm milk or after taking an antacid! Explain that taking it with milk melts the protective coat inside the stomach and causes severe stomach cramps.
- Meal & Clock Timing Instruction: Oral EC Tablet: Swallow whole with water at bedtime. CRITICAL MILK & ANTACID BAN: Never take within 1 hour of milk, dairy products, antacids, or PPIs/H2-blockers! (Oral: At bedtime (10:00 PM) for predictable morning evacuation (06:00–08:00 AM).)
- Missed Dose Protocol: Used PRN/short-term; if forgotten at bedtime, do not take in the morning if going out (as cramping evacuation will occur 6–10 hours later during the afternoon).
- Geriatric Dispensing Pearl: Prefer osmotic laxatives (Polyethylene Glycol or Lactulose) for daily chronic constipation in elderly CGHS patients; reserve Bisacodyl for rescue use (if no stool for 3 days) to avoid abdominal cramping, electrolyte loss, and syncope.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Enteric-Coated (Gastro-Resistant) Tablets: 5 mg; Rectal Suppositories: 5 mg (paediatric), 10 mg (adult)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 05 [5.9] (p. 64)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [5.13] Digestive Enzymes (Pancreatin & Fungal Diastase + Pepsin Preparations) — Exocrine Pancreatic / Digestive Enzyme Replacement (Lipase, Amyla
- [5.14] Dexlansoprazole & Ilaprazole — Modified Dual-Delayed-Release & Long-Half-Life Proton-Pump Inhibi
- [5.15] Itopride Hydrochloride & Acotiamide — Peripheral D2 Antagonist + Acetylcholinesterase Inhibitor Gastrop
- [5.16] Metoclopramide Hydrochloride — Central & Peripheral Dopamine D2 Antagonist & 5-HT4 Agonist Antie
